Key result
Therapeutic-dose anticoagulation shows no benefit over prophylactic dosing for major 30-day outcomes in COVID-19.
Why the study?
Prior studies evaluating therapeutic-dose anticoagulation in patients hospitalized with COVID-19 had reported conflicting results.
Does therapeutic-dose anticoagulation reduce the 30-day composite of mortality, ICU requirement, systemic thromboembolism, or ischemic stroke in noncritically ill patients hospitalized with COVID-19 compared with prophylactic-dose enoxaparin?
RCT (n=3,398)
Open-label
Block randomization stratified by center, admission type, and age
Yes
Does therapeutic-dose anticoagulation reduce the 30-day composite of mortality, ICU requirement, systemic thromboembolism, or ischemic stroke in noncritically ill patients hospitalized with COVID-19 compared with prophylactic-dose enoxaparin?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“If there is incomplete adherence to the trial protocol, ITT analyses may provide misleading estimates of the effect of a particular intervention when the intervention is used as indicated. This becomes particularly relevant when there are clear competing risks associated with an intervention (as is the case with anticoagulation), and the clinician must weigh the magnitude of potential risk against the magnitude of potential benefit.”
“What we learned from this trial is that many patients hospitalized with COVID-19 with pulmonary involvement, but not yet in the intensive care unit (ICU), will benefit from high-dose subcutaneous enoxaparin or oral apixaban to inhibit thrombosis and the progression of the disease. This is the first study to show that high-dose anticoagulation may improve survival in this patient population—a major finding since COVID-19 deaths are still prevalent.”
In noncritically ill patients hospitalized with COVID-19, therapeutic-dose anticoagulation did not significantly reduce the primary composite outcome of mortality, ICU requirement, or thromboembolism, but it did significantly reduce all-cause mortality and the need for intubation compared with prophylactic-dose anticoagulation.
Background Prior studies of therapeutic-dose anticoagulation in patients with COVID-19 have reported conflicting results. Objectives We sought to determine the safety and effectiveness of therapeutic-dose anticoagulation in noncritically ill patients with COVID-19. Methods Patients hospitalized with COVID-19 not requiring intensive care unit treatment were randomized to prophylactic-dose enoxaparin, therapeutic-dose enoxaparin, or therapeutic-dose apixaban. The primary outcome was the 30-day composite of all-cause mortality, requirement for intensive care unit–level of care, systemic thromboembolism, or ischemic stroke assessed in the combined therapeutic-dose groups compared with the prophylactic-dose group. Results Between August 26, 2020, and September 19, 2022, 3,398 noncritically ill patients hospitalized with COVID-19 were randomized to prophylactic-dose enoxaparin (n = 1,141), therapeutic-dose enoxaparin (n = 1,136), or therapeutic-dose apixaban (n = 1,121) at 76 centers in 10 countries. The 30-day primary outcome occurred in 13.2% of patients in the prophylactic-dose group and 11.3% of patients in the combined therapeutic-dose groups (HR: 0.85; 95% CI: 0.69-1.04; P = 0.11). All-cause mortality occurred in 7.0% of patients treated with prophylactic-dose enoxaparin and 4.9% of patients treated with therapeutic-dose anticoagulation (HR: 0.70; 95% CI: 0.52-0.93; P = 0.01), and intubation was required in 8.4% vs 6.4% of patients, respectively (HR: 0.75; 95% CI: 0.58-0.98; P = 0.03). Results were similar in the 2 therapeutic-dose groups, and major bleeding in all 3 groups was infrequent. Conclusions Among noncritically ill patients hospitalized with COVID-19, the 30-day primary composite outcome was not significantly reduced with therapeutic-dose anticoagulation compared with prophylactic-dose anticoagulation. However, fewer patients who were treated with therapeutic-dose anticoagulation required intubation and fewer died (FREEDOM COVID [FREEDOM COVID Anticoagulation Strategy]; NCT04512079)
No takes yet. Share an insight, caveat, or question.
Stone et al. (2023) conducted an RCT in COVID-19 (n=3,398). Therapeutic-dose anticoagulation (enoxaparin or apixaban) vs. Prophylactic-dose enoxaparin (40 mg subcutaneously every day) was evaluated on 30-day composite of all-cause mortality, requirement for intensive care unit-level of care, systemic thromboembolism, or ischemic stroke (HR 0.85, 95% CI 0.69-1.04, p=0.11). Therapeutic-dose anticoagulation did not reduce the 30-day primary composite outcome compared with prophylactic-dose anticoagulation in noncritically ill patients hospitalized with COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: